Amelioration of cerebral ischemia–reperfusion injury based on liposomal drug delivery system with asialo-erythropoietin

Ishii, Takayuki; Asai, Tomohiro; Oyama, Dai; Fukuta, Tatsuya; Yasuda, Nodoka; Shimizu, Kosuke; Minamino, Tetsuo; Oku, Naoto

doi:10.1016/j.jconrel.2012.02.004

Cited by 102 publications

(66 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, when liposomes were associated with contrast agents, researchers observed that they quickly accumulated in the ischemic zone. 134,143,148,152,190 Some formulations have demonstrated their ability to improve in vivo activity of drugs, such as chrysophanol, 133 dexamethasone phosphate, 154 nerve growth factor, 170 Xe, 150,158 FK506, 149 isopropylidene-shikimic acid, 151 asialo-erythropoietin, 153 antisense oligonucleotides, 165 plasmids, 174 quercetin, 166,168 fasudil, 176 nitric oxide, 146 N-acetylleucyl-leucyl-norleucine amide, 178 and a combination of synergistic drugs. 156,175 Very recently, a promising uncoupling new drug -ZL006 (5-(3, 5-dichloro-2-hydroxybenzylamino)-2-hydroxybenzoic acid) -was developed for stroke treatment.…”

Section: Stroke or Cerebral Ischemiamentioning

confidence: 99%

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Vieira

Gamarra

2016

IJN

356

238

View full text Add to dashboard Cite

This review summarizes articles that have been reported in literature on liposome-based strategies for effective drug delivery across the blood–brain barrier. Due to their unique physicochemical characteristics, liposomes have been widely investigated for their application in drug delivery and in vivo bioimaging for the treatment and/or diagnosis of neurological diseases, such as Alzheimer’s, Parkinson’s, stroke, and glioma. Several strategies have been used to deliver drug and/or imaging agents to the brain. Covalent ligation of such macromolecules as peptides, antibodies, and RNA aptamers is an effective method for receptor-targeting liposomes, which allows their blood–brain barrier penetration and/or the delivery of their therapeutic molecule specifically to the disease site. Additionally, methods have been employed for the development of liposomes that can respond to external stimuli. It can be concluded that the development of liposomes for brain delivery is still in its infancy, although these systems have the potential to revolutionize the ways in which medicine is administered.

show abstract

Section: Stroke or Cerebral Ischemiamentioning

confidence: 99%

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Vieira

Gamarra

2016

IJN

356

238

View full text Add to dashboard Cite

show abstract

“…Liposomes accumulated in the ischemic side of the brain. 75,76) Moreover, liposomes approximately 100 nm in size accumulated to a greater extent than those about 200 nm in size; and those about 800 nm in size did not accumulate in the ischemic brain. 77) Figure 3 also shows that once accumulated the liposomes resided there for a long period of time.…”

Section: Liposomal Traffic In the Brainmentioning

confidence: 95%

Innovations in Liposomal DDS Technology and Its Application for the Treatment of Various Diseases

Oku

2017

Biological & Pharmaceutical Bulletin

Self Cite

View full text Add to dashboard Cite

Liposomes have been widely used as drug carriers in the field of drug delivery systems (DDS), and they are thought to be ideal nano-capsules for targeting DDS after being injected into the bloodstream. In general, DDS drugs meet the needs of aged and super-aged societies, since the administration route of drugs can be changed, the medication frequency reduced, the adverse effects of drugs suppressed, and so on. In fact, a number of liposomal drugs have been launched and used worldwide including liposomal anticancer drugs, and these drugs have appeared on the market owing to various innovations in liposomal DDS technologies. The accumulation of long-circulating liposomes in cancer tissue is driven by the enhanced permeability and retention (EPR) effect. In this review, liposome-based targeting DDS for cancer therapy is briefly discussed. Since cancer angiogenic vessels are the ideal target of drug carriers after their injection and are critical for cancer growth, damaging of these neovessels has been an approach for eradicating cancer cells. Also, the usage of liposomal DDS for the treatment of ischemic stroke is possible, since we observed that PEGylated liposomes accumulate in the site of cerebral ischemia in transient middle cerebral artery occlusion (t-MCAO) model rats. Interestingly, liposomes carrying neuroprotectants partly suppress ischemia/reperfusion injury of these model rats, suggesting that the EPR effect also works in ischemic diseases by causing an increase in the permeability of the blood vessel endothelium. The potential of liposomal DDS against life-threatening diseases might thus be attractive for supporting long-lived societies.

show abstract

“…In a model of transient cerebral ischemia, it was found that accumulation of AEPOloaded PEGylated liposomes (AEPO-PL) occurred rapidly after administration if given at an early stage of reperfusion. 115 This is beneficial because, as most neurological damage occurs during reperfusion, the presence of a cytoprotectant such as AEPO would probably limit the extent of damage; however, accumulation of AEPO-PL in the ischemic region was low when given 6 and 24 hours after reperfusion. In terms of efficacy, the researchers showed that, compared to a 30% reduction of infarct volume in animals treated with naked AEPO, those treated with AEPO-PL showed a 70% reduction of the infarct volume.…”

Section: Liposomesmentioning

confidence: 99%

“…In terms of efficacy, the researchers showed that, compared to a 30% reduction of infarct volume in animals treated with naked AEPO, those treated with AEPO-PL showed a 70% reduction of the infarct volume. 115 This was probably due to the longer retention of AEPO-PL in the infarct region compared to the short half-life of its naked counterpart.…”

Section: Liposomesmentioning

confidence: 99%

Nanoscale drug delivery systems and the blood–brain barrier

Alyautdin¹,

Khalin²,

Nafeeza³

et al. 2014

IJN

121

View full text Add to dashboard Cite

The protective properties of the blood–brain barrier (BBB) are conferred by the intricate architecture of its endothelium coupled with multiple specific transport systems expressed on the surface of endothelial cells (ECs) in the brain’s vasculature. When the stringent control of the BBB is disrupted, such as following EC damage, substances that are safe for peripheral tissues but toxic to neurons have easier access to the central nervous system (CNS). As a consequence, CNS disorders, including degenerative diseases, can occur independently of an individual’s age. Although the BBB is crucial in regulating the biochemical environment that is essential for maintaining neuronal integrity, it limits drug delivery to the CNS. This makes it difficult to deliver beneficial drugs across the BBB while preventing the passage of potential neurotoxins. Available options include transport of drugs across the ECs through traversing occludins and claudins in the tight junctions or by attaching drugs to one of the existing transport systems. Either way, access must specifically allow only the passage of a particular drug. In general, the BBB allows small molecules to enter the CNS; however, most drugs with the potential to treat neurological disorders other than infections have large structures. Several mechanisms, such as modifications of the built-in pumping-out system of drugs and utilization of nanocarriers and liposomes, are among the drug-delivery systems that have been tested; however, each has its limitations and constraints. This review comprehensively discusses the functional morphology of the BBB and the challenges that must be overcome by drug-delivery systems and elaborates on the potential targets, mechanisms, and formulations to improve drug delivery to the CNS.

show abstract

Amelioration of cerebral ischemia–reperfusion injury based on liposomal drug delivery system with asialo-erythropoietin

Cited by 102 publications

References 36 publications

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Innovations in Liposomal DDS Technology and Its Application for the Treatment of Various Diseases

Nanoscale drug delivery systems and the blood–brain barrier

Contact Info

Product

Resources

About

Amelioration of cerebral ischemia–reperfusion injury based on liposomal drug delivery system with asialo-erythropoietin

Cited by 102 publications

References 36 publications

Getting into the brain: liposome-based strategies for effective drug delivery across the blood&ndash;brain barrier

Getting into the brain: liposome-based strategies for effective drug delivery across the blood&ndash;brain barrier

Innovations in Liposomal DDS Technology and Its Application for the Treatment of Various Diseases

Nanoscale drug delivery systems and the blood&ndash;brain barrier

Contact Info

Product

Resources

About

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier

Nanoscale drug delivery systems and the blood–brain barrier